BR100 Decreased By (-0.4%)
BR30 Decreased By (-0.65%)
KSE100 Decreased By (-0.29%)
KSE30 Decreased By (-0.22%)
AGHA 6.56 Decreased By ▼ -0.11 (-1.65%)
BECO 4.40 Increased By ▲ 0.05 (1.15%)
BML 55.89 Decreased By ▼ -0.28 (-0.5%)
BOP 30.05 Decreased By ▼ -0.07 (-0.23%)
CNERGY 12.75 Decreased By ▼ -0.23 (-1.77%)
CSIL 5.21 Decreased By ▼ -0.10 (-1.88%)
FCCL 51.00 Decreased By ▼ -0.65 (-1.26%)
FFL 14.43 Decreased By ▼ -0.06 (-0.41%)
FNEL 1.22 Increased By ▲ 0.01 (0.83%)
KEL 5.97 Decreased By ▼ -0.09 (-1.49%)
KOSM 5.58 Decreased By ▼ -0.26 (-4.45%)
LOTCHEM 26.15 Decreased By ▼ -0.02 (-0.08%)
MLCF 90.33 Decreased By ▼ -0.90 (-0.99%)
NBP 161.45 Decreased By ▼ -2.74 (-1.67%)
NCPL 52.55 Decreased By ▼ -0.63 (-1.18%)
NPL 57.98 Decreased By ▼ -1.14 (-1.93%)
OGDC 315.40 Increased By ▲ 2.01 (0.64%)
PACE 9.70 Decreased By ▼ -0.07 (-0.72%)
PAEL 34.73 Decreased By ▼ -0.51 (-1.45%)
PIBTL 14.23 Decreased By ▼ -0.48 (-3.26%)
PPL 221.00 Decreased By ▼ -0.36 (-0.16%)
PRL 90.89 Decreased By ▼ -0.33 (-0.36%)
PTC 59.25 Increased By ▲ 0.06 (0.1%)
SSGC 23.39 Increased By ▲ 0.09 (0.39%)
TBL 8.65 Decreased By ▼ -0.10 (-1.14%)
TELE 7.40 Decreased By ▼ -0.21 (-2.76%)
TPL 21.00 Decreased By ▼ -1.03 (-4.68%)
TPLP 12.02 Decreased By ▼ -0.54 (-4.3%)
TREET 21.33 Decreased By ▼ -0.40 (-1.84%)
TRG 54.35 Decreased By ▼ -1.44 (-2.58%)
Pakistan Print edition: 2019-12-18

ICI Pakistan strengthens its partnership with AstraZeneca

ICI Pakistan Limited and AstraZeneca UK Limited confirmed the renewal of their longstanding relationship in the cardiovascular and oncology segment. ICI Pakistan is a longstanding distributor of AstraZeneca's high quality life-saving medicines. AstraZenec
Published Updated

ICI Pakistan Limited and AstraZeneca UK Limited confirmed the renewal of their longstanding relationship in the cardiovascular and oncology segment. ICI Pakistan is a longstanding distributor of AstraZeneca's high quality life-saving medicines. AstraZeneca GCC Country President Ismail Shehada visited ICI Pakistan and met with key stakeholders during his two-day visit to renew the existing relationship and explore potential new avenues of partnership to alleviate suffering and build a platform for patients and caregivers to treat high burden of diseases in Pakistan.

Gracing the ceremony at the ICI Pakistan Head Office, Mike Nithavrianakis, British Deputy High Commissioner Karachi and Trade Director for Pakistan, emphasised the importance of building a sustainable ecosystem to provide much needed care to patients in Pakistan.

Speaking on the occasion, ICI Pakistan Chief Executive Asif Jooma said, "ICI Pakistan has been in the pharmaceuticals business since 1993 and seeks to further enhance its global partnerships and introduce innovative products."

Shehada added, "AstraZeneca has an interest in the region and intends to grow its business through providing improved solutions for patients." He further stated, "AstraZeneca is a full healthcare company providing not only innovative molecules but which believes in going beyond medication alone by looking to introduce customised solutions to meet local needs and requirements."-PR

Copyright Business Recorder, 2019

Comments

Comments are closed for this article.